Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Interest & Investment Income came in at $28.1 million in Q2 2026, up 2.39% YoY from $27.5 million in Q2 2025, and up 5.81% on a QoQ basis from $26.6 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Interest & Investment Income data on file, last reported at $28.1 million in Q2 2026.
- Quarterly Interest & Investment Income rose 2.39% year-over-year to $28.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $110.1 million (down 7.77% YoY) and the FY2025 annual result came in at $111.5 million, down 8.63% from the prior year.
- Interest & Investment Income climbed to $28.1 million in Q2 2026, from $26.6 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $35.8 million in Q4 2022 to a low of -$7.2 million in Q1 2022.
- A 5-year average of $23.4 million and a median of $27.8 million in 2025 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 12318.75% in 2022, down 1703.78% in 2022.
- Tracing ALNY's Interest & Investment Income over 5 years: stood at $35.8 million in 2022, then declined by 15.1% to $30.4 million in 2023, then climbed by 2.02% to $31.0 million in 2024, then retreated by 14.15% to $26.6 million in 2025, then rose by 5.68% to $28.1 million in 2026.
- The last three Interest & Investment Income figures came in at $28.1 million (Q2 2026), $26.6 million (Q1 2026), and $26.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.14 Mn |
| Mar 31, 2026 | 26.60 Mn |
| Dec 31, 2025 | 109.65 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | -343,000.00 |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | 31.02 Mn |
| Sep 30, 2024 | 9.08 Mn |
| Jun 30, 2024 | -727,000.00 |
| Mar 31, 2024 | 29.65 Mn |
| Dec 31, 2023 | 7.04 Mn |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | -2.03 Mn |
| Mar 31, 2023 | 18.66 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 7.82 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | -7.22 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | -64,000.00 |